Skip to main content

Displaying 1761 - 1780 of 2074

Feb12

Unilateral Effects Analysis and Litigation Workshop

-
The Federal Trade Commission is planning to host a public workshop on February 12, 2008 to examine the application of unilateral effects theory to mergers of firms that sell competing, but...
Feb13

Broadband Connectivity Competition Policy

-
The FTC hosted a public workshop on that brought together experts from business, government, and the technology sector, consumer advocates, and academics to explore competition and consumer protection...

Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of

A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.

There is a related federal proceeding and two related administrative proceedings:

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0610139
Docket Number
C-4172

FTC Resolves Aloha Petroleum Litigation

Date
The Federal Trade Commission today announced that, because of changed circumstances, it has asked the Federal District Court for the District of Hawaii to dismiss the FTC’s complaint seeking an...